309 related articles for article (PubMed ID: 27486833)
21. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
22. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
23. Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities.
Hendriks CM; Penning TM; Zang T; Wiemuth D; Gründer S; Sanhueza IA; Schoenebeck F; Bolm C
Bioorg Med Chem Lett; 2015 Oct; 25(20):4437-40. PubMed ID: 26372652
[TBL] [Abstract][Full Text] [Related]
24. In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
Li C; Zhao Y; Zheng X; Zhang H; Zhang L; Chen Y; Li Q; Hu X
Chem Biol Interact; 2016 Jun; 253():60-5. PubMed ID: 27163852
[TBL] [Abstract][Full Text] [Related]
25. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
26. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
27. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
29. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
[TBL] [Abstract][Full Text] [Related]
31. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
33. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
34. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
35. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
36. 3D-QSAR studies of 3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids as AKR1C3 inhibitors: Highlight the importance of molecular docking in conformation generation.
Zheng X; Wu Y; Wu D; Wang X; Zhang C; Guo X; Luo HB
Bioorg Med Chem Lett; 2016 Dec; 26(23):5631-5638. PubMed ID: 27847272
[TBL] [Abstract][Full Text] [Related]
37. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
38. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Brozic P; Golob B; Gomboc N; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):233-5. PubMed ID: 16337332
[TBL] [Abstract][Full Text] [Related]
39. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
